Mission Pharmacal for women and babies
This article was originally published in The Tan Sheet
Executive SummaryThe San Antonio-based firm extends its products marketed to women into OTC lotions with the acquisition of Dr. Smith's Diaper Ointment from innovator Esrubar and marketer Beta Dermaceuticals. Mission Pharmacal did not disclose financial terms of the Aug. 31 deal, which also includes Rash-n-All Ointment. The firm already markets CitraNatal prenatal vitamins and Ferralet 90 iron therapy Rx products, and will give samples of Dr. Smith's products to health care providers who buy its prescription drugs and can recommend the ointment to patients, said company President Neill Walsdorf, Jr. According to Information Resources Inc., Dr. Smith's sales were $1.85 million, or 1.82 percent of the category, in the 52 weeks ending Aug. 9, excluding sales at Wal-Mart, club stores and convenience stores. Desitin leads the baby ointment category at $15.7 million, or 15.37 percent, Chicago-based IRI data show. Mission Pharmacal expects to extend Dr. Smith's Diaper Ointment nationwide in 2010 before growing Rash-n-All sales
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.